AbbVie Has 189 Research Projects in Shanghai and Over USD 10 Billion in China Deals
AbbVie, a biopharmaceutical company focused on immunology, neuroscience and oncology, has established 189 research projects in Shanghai with related investment of nearly RMB 400 million, according to global vice president Dong Lijun. In recent years the company has signed cooperation projects with Chinese innovative drugmakers worth more than USD 10 billion in total.
AbbVie is a biopharmaceutical company whose business focuses on areas including immunology, neuroscience and oncology. The company has established a cumulative 189 research projects in Shanghai, with related investment of nearly RMB 400 million.
In recent years, AbbVie has signed cooperation projects with Chinese innovative drug companies, with a total value exceeding USD 10 billion.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 55/100 and 70% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 55
- Confidence
- 70%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 50
- Confidence
- 65%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.